BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer

导出原文传递

翻译打印收藏纠错

作者： Shi, Ruoshi ^[1] ; Martins Filho, Sebastiao N. ; Li, Ming ; Fares, Aline ; Weiss, Jessica ; Nhu-An Pham ; Ludkovski, Olga ; Raghavan, Vibha ; Li, Quan ; Ravi, Deepti ; Cabanero, Michael ; Moghal, Nadeem ; Leighl, Natasha B. ; Bradbury, Penelope ; Sacher, Adrian ; Shepherd, Frances A. ; Yasufuku, Kazuhiro ; Tsao, Ming-Sound ; Liu, Geoffrey

作者单位： Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada ^[1]

关键词 Lung adenocarcinoma Patient-derived xenograft PDX EML4-ALKv1 ALK inhibitor Drug resistance NOD-SCID mice Dabrafenib Capmatinib

发布时间 2021-02-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Lung cancer

2020年146卷

78-85页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer

Lung cancer

相似文献

Lung cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer

Lung cancer

相似文献

Lung cancer

相关期刊

检索历史清除